These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 14715180

  • 1. Azimilide decreases recurrent ventricular tachyarrhythmias in patients with implantable cardioverter defibrillators.
    Singer I, Al-Khalidi H, Niazi I, Tchou P, Simmons T, Henthorn R, Holroyde M, Brum J.
    J Am Coll Cardiol; 2004 Jan 07; 43(1):39-43. PubMed ID: 14715180
    [Abstract] [Full Text] [Related]

  • 2. Placebo-controlled, randomized clinical trial of azimilide for prevention of ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillator.
    Dorian P, Borggrefe M, Al-Khalidi HR, Hohnloser SH, Brum JM, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, van der Laan M, Holroyde MJ, Singer I, Pratt CM, SHock Inhibition Evaluation with azimiLiDe (SHIELD) Investigators.
    Circulation; 2004 Dec 14; 110(24):3646-54. PubMed ID: 15533855
    [Abstract] [Full Text] [Related]

  • 3. Results of a curtailed randomized controlled trial, evaluating the efficacy and safety of azimilide in patients with implantable cardioverter-defibrillators: The SHIELD-2 trial.
    Robinson VM, Bharucha DB, Mahaffey KW, Dorian P, Kowey PR, SHIELD-2 Investigators.
    Am Heart J; 2017 Mar 14; 185():43-51. PubMed ID: 28267474
    [Abstract] [Full Text] [Related]

  • 4. The efficacy of azimilide in the treatment of atrial fibrillation in the presence of left ventricular systolic dysfunction: results from the Azimilide Postinfarct Survival Evaluation (ALIVE) trial.
    Pratt CM, Singh SN, Al-Khalidi HR, Brum JM, Holroyde MJ, Marcello SR, Schwartz PJ, Camm AJ, ALIVE Investigators.
    J Am Coll Cardiol; 2004 Apr 07; 43(7):1211-6. PubMed ID: 15063432
    [Abstract] [Full Text] [Related]

  • 5. Design of the SHock Inhibition Evaluation with Azimilide (SHIELD) study: a novel method to assess antiarrhythmic drug effect in patients with an implantable cardioverter-defibrillator.
    Pratt CM, Dorian P, Al-Khalidi HR, Brum JM, Borggrefe M, Tatla DS, Brachmann J, Myerburg RJ, Cannom DS, Holroyde MJ, van der Laan M, Hohnloser SH, SHIELD Investigators.
    Am J Cardiol; 2005 Jan 15; 95(2):274-6. PubMed ID: 15642569
    [Abstract] [Full Text] [Related]

  • 6. Azimilide reduces emergency department visits and hospitalizations in patients with an implantable cardioverter-defibrillator in a placebo-controlled clinical trial.
    Dorian P, Al-Khalidi HR, Hohnloser SH, Brum JM, Dunnmon PM, Pratt CM, Holroyde MJ, Kowey P, Shock Inhibition Evaluation with Azimilide Investigators.
    J Am Coll Cardiol; 2008 Sep 23; 52(13):1076-83. PubMed ID: 18848141
    [Abstract] [Full Text] [Related]

  • 7. Adjunctive therapy for recurrent ventricular tachycardia in patients with implantable cardioverter defibrillators.
    Reiffel JA.
    Curr Cardiol Rep; 2007 Sep 23; 9(5):381-6. PubMed ID: 17877933
    [Abstract] [Full Text] [Related]

  • 8. Antiarrhythmic drugs in patients with implantable cardioverter-defibrillators.
    Bollmann A, Husser D, Cannom DS.
    Am J Cardiovasc Drugs; 2005 Sep 23; 5(6):371-8. PubMed ID: 16259525
    [Abstract] [Full Text] [Related]

  • 9. Electrical storm in patients with an implantable defibrillator: incidence, features, and preventive therapy: insights from a randomized trial.
    Hohnloser SH, Al-Khalidi HR, Pratt CM, Brum JM, Tatla DS, Tchou P, Dorian P, SHock Inhibition Evaluation with AzimiLiDe (SHIELD) Investigators.
    Eur Heart J; 2006 Dec 23; 27(24):3027-32. PubMed ID: 17050586
    [Abstract] [Full Text] [Related]

  • 10. The effect of spironolactone on ventricular tachyarrhythmias in patients with implantable cardioverter-defibrillators.
    Zarraga IG, Dougherty CM, MacMurdy KS, Raitt MH.
    Circ Arrhythm Electrophysiol; 2012 Aug 01; 5(4):739-47. PubMed ID: 22773022
    [Abstract] [Full Text] [Related]

  • 11. Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response. Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators.
    Pritchett EL, Page RL, Connolly SJ, Marcello SR, Schnell DJ, Wilkinson WE.
    J Am Coll Cardiol; 2000 Sep 01; 36(3):794-802. PubMed ID: 10987602
    [Abstract] [Full Text] [Related]

  • 12. The azimilide post-infarct survival evaluation (ALIVE) trial.
    Camm AJ, Karam R, Pratt CM.
    Am J Cardiol; 1998 Mar 19; 81(6A):35D-39D. PubMed ID: 9537221
    [Abstract] [Full Text] [Related]

  • 13. Suppression of inducible ventricular arrhythmias by intravenous azimilide in dogs with previous myocardial infarction.
    Drexler AP, Micklas JM, Brooks RR.
    J Cardiovasc Pharmacol; 1996 Dec 19; 28(6):848-55. PubMed ID: 8961084
    [Abstract] [Full Text] [Related]

  • 14. The shocking story of azimilide.
    Hanna IR, Langberg JJ.
    Circulation; 2004 Dec 14; 110(24):3624-6. PubMed ID: 15596558
    [No Abstract] [Full Text] [Related]

  • 15. Cumulative experience of azimilide-associated torsades de pointes ventricular tachycardia in the 19 clinical studies comprising the azimilide database.
    Pratt CM, Al-Khalidi HR, Brum JM, Holroyde MJ, Schwartz PJ, Marcello SR, Borggrefe M, Dorian P, Camm AJ, Azimilide Trials Investigators.
    J Am Coll Cardiol; 2006 Aug 01; 48(3):471-7. PubMed ID: 16875971
    [Abstract] [Full Text] [Related]

  • 16. Antiarrhythmic effects of azimilide in paroxysmal supraventricular tachycardia: efficacy and dose-response.
    Page RL, Connolly SJ, Wilkinson WE, Marcello SR, Schnell DJ, Pritchett EL, Azimilide Supraventricular Arrhythmia Program (ASAP) Investigators.
    Am Heart J; 2002 Apr 01; 143(4):643-9. PubMed ID: 11923801
    [Abstract] [Full Text] [Related]

  • 17. Mortality in patients after a recent myocardial infarction: a randomized, placebo-controlled trial of azimilide using heart rate variability for risk stratification.
    Camm AJ, Pratt CM, Schwartz PJ, Al-Khalidi HR, Spyt MJ, Holroyde MJ, Karam R, Sonnenblick EH, Brum JM, AzimiLide post Infarct surVival Evaluation (ALIVE) Investigators.
    Circulation; 2004 Mar 02; 109(8):990-6. PubMed ID: 14967728
    [Abstract] [Full Text] [Related]

  • 18. Effect of elevated heart rate preceding the onset of ventricular tachycardia on antitachycardia pacing effectiveness in patients with implantable cardioverter defibrillators.
    Kouakam C, Lauwerier B, Klug D, Jarwe M, Marquié C, Lacroix D, Kacet S.
    Am J Cardiol; 2003 Jul 01; 92(1):26-32. PubMed ID: 12842240
    [Abstract] [Full Text] [Related]

  • 19. Azimilide for atrial fibrillation: clinical trial results and implications.
    Pritchett EL, Marcello SR.
    Card Electrophysiol Rev; 2003 Sep 01; 7(3):215-9. PubMed ID: 14739716
    [Abstract] [Full Text] [Related]

  • 20. Dofetilide reduces the frequency of ventricular arrhythmias and implantable cardioverter defibrillator therapies.
    Baquero GA, Banchs JE, Depalma S, Young SK, Penny-Peterson ED, Samii SM, Wolbrette DL, Naccarelli GV, Gonzalez MD.
    J Cardiovasc Electrophysiol; 2012 Mar 01; 23(3):296-301. PubMed ID: 21955243
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.